On October 31, 2019, BeiGene and Amgen announced a global strategic oncology collaboration for the commercialization of a series of Amgen’s cancer drugs in China and the development of 20 oncology assets in Amgen’s pipeline, with BeiGene responsible for development and commercialization in China.
The BeiGene-Amgen cooperation represents the largest ever US-China cross-border biotech transaction.
In connection with the collaboration, Amgen will purchase a 20.5% stake in BeiGene for approximately $2.7 billion in cash at $174.85 per American Depositary Share (ADS).